Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
July 26, 2022 07:30 ET
|
Reneo Pharmaceuticals, Inc.
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects...
Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 11, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
June 30, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results
May 10, 2022 16:05 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 23, 2022 16:05 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Senior Leadership Promotions
March 07, 2022 08:30 ET
|
Reneo Pharmaceuticals, Inc.
Michael P. Cruse appointed Chief Operating OfficerJennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals,...
Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference
February 02, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Changes to its Board of Directors
January 24, 2022 08:00 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 11, 2021 16:05 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences
November 01, 2021 16:05 ET
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...